LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

39.96 -0.55

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.3

Max

40.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

-95M

Verkäufe

1.7M

203M

EPS

-0.49

Gewinnspanne

-46.768

Angestellte

1,999

EBITDA

-12M

-111M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+48.58% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-762M

5.2B

Vorheriger Eröffnungskurs

40.51

Vorheriger Schlusskurs

39.96

Nachrichtenstimmung

By Acuity

29%

71%

80 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Mai 2025, 20:54 UTC

Akquisitionen, Fusionen, Übernahmen

PNC to Buy Private-Equity Agent Aqueduct Capital

20. Mai 2025, 20:50 UTC

Ergebnisse

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20. Mai 2025, 23:48 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20. Mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20. Mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20. Mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20. Mai 2025, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20. Mai 2025, 22:20 UTC

Top News

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20. Mai 2025, 22:00 UTC

Ergebnisse

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20. Mai 2025, 22:00 UTC

Ergebnisse

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20. Mai 2025, 22:00 UTC

Ergebnisse

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20. Mai 2025, 21:44 UTC

Ergebnisse

James Hardie Industries 4Q Adj EPS 36c >JHX

20. Mai 2025, 21:44 UTC

Ergebnisse

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20. Mai 2025, 21:44 UTC

Ergebnisse

James Hardie Industries 4Q EPS 10c >JHX

20. Mai 2025, 21:44 UTC

Ergebnisse

James Hardie Industries 4Q Sales $972M >JHX

20. Mai 2025, 20:52 UTC

Top News

Elon Musk to Cut Back Political Spending -- 3rd Update

20. Mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20. Mai 2025, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20. Mai 2025, 20:28 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20. Mai 2025, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20. Mai 2025, 20:22 UTC

Ergebnisse

XP 1Q Adj EPS BRL2.29 >XP

20. Mai 2025, 20:22 UTC

Ergebnisse

XP 1Q Rev BRL4.345B >XP

20. Mai 2025, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20. Mai 2025, 20:20 UTC

Top News

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20. Mai 2025, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20. Mai 2025, 20:11 UTC

Top News

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20. Mai 2025, 20:09 UTC

Ergebnisse

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

20. Mai 2025, 20:08 UTC

Ergebnisse

Palo Alto Networks Sees FY25 Adj EPS $3.26-Adj EPS $3.28 >PANW

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

48.58% Vorteil

12-Monats-Prognose

Durchschnitt 59.79 USD  48.58%

Hoch 70 USD

Tief 52 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

20

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

80 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.